中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 11
Nov.  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(11): 2510-2513

Short-term mortality and death causes after TACE in patients with primary liver cancer

DOI: 10.3969/j.issn.1001-5256.2022.11.014
  • 1.

    Department of Interventional Radiology, First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, China

  • 2.

    Department of Interventional Radiology, Kizilsu People's Hospital of Kirgiz Autonomous Prefecture, Kizilsu Kirgiz Autonomous Prefecture, Xinjiang 845355, China

More Information
  • Corresponding author: LI Zhi, lizhisoochow@suda.edu.cn(ORCID: 0000-0001-7613-4193)
  • Received Date: 2022-04-08
  • Accepted Date: 2022-08-01
  • Published Date: 2022-11-20
    Abstract
  •   Objective  To investigate the short-term mortality of transcatheter arterial chemoembolization (TACE) in patients with primary liver cancer, and explore the possible causes of death and countermeasures.  Methods  All patients who underwent TACE at the Department of Interventional Radiology, First Affiliated Hospital of Soochow University from January 2015 to December 2020 were studied, but those with metastatic liver cancer or receiving combined treatment were excluded. The clinical and imaging data of all patients were collected before and 30 days after TACE, and the clinical characteristics of the patients with short-term postoperative death were analyzed. Death within 30 days after TACE was defined as short-term death.  Results  A total of 1466 TACE in 741 patients with primary liver cancer were included. Ten patients (10/741, 1.35%) died within 30 days after TACE, with a mortality rate of 0.68% for all TACE. The mortality rate of d-TACE and c-TACE was 1.62% (3/185) and 0.55 % (7/1281), respectively. The mortality rates of patients at China Liver Cancer Staging Ⅰ, Ⅱ, and Ⅲ stages were 0.45% (2/448), 0.33% (2/599), and 1.43% (6/419), respectively. The mean diameter of the largest lesion in death cases was 10.1±0.8 cm. The possible causes of death were liver failure (4 cases), rupture bleeding (3 cases), myelotoxicity (1 case), pulmonary embolism (1 case), and heart failure (1 case).  Conclusion  The mortality rate after TACE in patients with primary liver cancer is low, with occasional short-term postoperative deaths. The death cases are characterized by a large tumor volume, and the most common causes of short-term death are liver failure and rupture bleeding.

     

    • FullText(HTML)
  • loading
    • References(12)
  • [1]
    Bureau of Medical Administration, National Health Commission of the People's Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)[J]. J Clin Hepatol, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007.

    中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 临床肝胆病杂志, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007.
    [2]
    PARK JW, CHEN M, COLOMBO M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study[J]. Liver Int, 2015, 35(9): 2155-2166. DOI: 10.1111/liv.12818.
    [3]
    YANG JS, TIAN R, ZHANG XZ, et al. Analysis of short-term deat h after transcatheter hepatic arterial chemoembolization in 265 patients with liver cancer[J]. Clin Med China, 2001, 17 (12): 44-45. DOI: 10.3760/cma.j.issn. 1008-6315.2001.12.027.

    杨劲松, 田韧, 张学忠, 等. 265例肝癌患者肝动脉化疗栓塞后近期死亡原因分析[J]. 中国综合临床, 2001, 17(12): 44-45. DOI: 10.3760/cma.j.issn.1008-6315.2001.12.027.
    [4]
    Special Committee of Clinical Diagnosis and Treatment Guidelines of Interventional Doctors Branch of Chinese Medical Doctor Association. Chinese clinical practice guidelines for the treatment of trantraarterial chemoembolization (TACE) in hepatocellular carcinoma (2021 edition)[J]. Chin J Int Med, 2021, 60(7): 599-614. DOI: 10.3760/cma.j.cn112137-20210425-00991.

    中国医师协会介入医师分会临床诊疗指南专委会. 中国肝细胞癌经动脉化疗栓塞(TACE)治疗临床实践指南(2021年版)[J]. 中华内科杂志, 2021, 60(7): 599-614. DOI: 10.3760/cma.j.cn112137-20210425-00991.
    [5]
    LI Z, NI CF. Technical details and progress of transcatheter hepatic arterial chemoembol ization[J/CD]. Chin J Inter Rad(Electronic Edition), 2018, 6(2): 127-132. DOI: 10.3877/cma.j.issn.2095-5782.2018.02.008.

    李智, 倪才方. 经导管肝动脉化疗栓塞术的技术细节与进展[J/CD]. 中华介入放射学电子杂志, 2018, 6(2): 127-132. DOI: 10.3877/cma.j.issn.2095-5782.2018.02.008.
    [6]
    LENCIONI R, DE BAERE T, SOULEN MC, et al. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data[J]. Hepatology, 2016, 64(1): 106-116. DOI: 10.1002/hep.28453.
    [7]
    ZHANG L, SUN JH, JI JS, et al. Imaging changes and clinical complications after drug-eluting bead versus conventional transarterial chemoembolization for unresectable hepatocellular carcinoma: multicenter study[J]. AJR Am J Roentgenol, 2021, 217(4): 933-943. DOI: 10.2214/AJR.20.24708.
    [8]
    SHIMOSE S, IWAMOTO H, TANAKA M, et al. Increased arterio-portal shunt formation after drug-eluting beads TACE for hepatocellular carcinoma[J]. Oncology, 2020, 98(8): 558-565. DOI: 10.1159/000507262.
    [9]
    HU H, CHEN GF, YUAN W, et al. Microwave ablation with chemoembolization for large hepatocellular carcinoma in patients with cirrhosis[J]. Int J Hyperthermia, 2018, 34(8): 1351-1358. DOI: 10.1080/02656736.2018.1462536.
    [10]
    YANG GW, ZHAO Q, QIAN S, et al. Percutaneous microwave ablation combined with simultaneous transarterial chemoembolization for the treatment of advanced intrahepatic cholangiocarcinoma[J]. Onco Targets Ther, 2015, 8: 1245-1250. DOI: 10.2147/OTT.S84764.
    [11]
    ROTH GS, BENHAMOU M, TEYSSIER Y, et al. Comparison of trans-arterial chemoembolization and bland embolization for the treatment of hepatocellular carcinoma: a propensity score analysis[J]. Cancers (Basel), 2021, 13(4): 812. DOI: 10.3390/cancers13040812.
    [12]
    FACCIORUSSO A, BELLANTI F, VILLANI R, et al. Transarterial chemoembolization vs bland embolization in hepatocellular carcinoma: A meta-analysis of randomized trials[J]. United European Gastroenterol J, 2017, 5(4): 511-518. DOI: 10.1177/2050640616673516.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (511) PDF downloads(63) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return